Daraxonrasib

N/A

Report date: 2026/04/07 20:00:20
NME

Base Information

Drug NameDaraxonrasib
Drug Alias NameRAS(ON) inhibitorRASMULTI(ON) InhibitorRMC-6236Ras-IN-2
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGTPase Ras inhibitors
TargetsGTPase Ras
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSingapore +[21] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRevolution Medicines Inc
China Registration ClassN/A

Develop Information

Active CompaniesRevolution Medicines Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A